Rationale and protocol of CML study: Cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia

Tumori

Volumn 102, Issue 2, 2016, Pages 217-221

  Riva, Silvia ^a,b   Mazzocco, Ketti ^a,b   Pravettoni, Gabriella ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chronic myeloid leukemia; Decision making; Discontinuation; Medical choices; Personality; Risk perception

Indexed keywords

ARTICLE; ATTITUDE ASSESSMENT; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; COGNITION; DISEASE SEVERITY; EMOTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NEED FOR CLOSURE SCALE; OBSERVATIONAL STUDY; PASSIVE RISK TAKING SCALE; PATIENT ATTITUDE; PRACTICE GUIDELINE; QUESTIONNAIRE; RATING SCALE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL DECISION MAKING; CLINICAL TRIAL; EUROPE; FEMALE; INTERNATIONAL COOPERATION; ITALY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT; PERSONALITY; PERSONALITY TEST; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL DECISION-MAKING; COGNITION; EMOTIONS; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; ITALY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATIENTS; PERSONALITY; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; WITHHOLDING TREATMENT;

EID: 84969262681     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000451     Document Type: Article

References (24)

1. Mahon FX. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol. 2015;94(Suppl 2):S187-S193.
2. Kimura S, Ashihara E, Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol. 2006;7(5):371-379.
3. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109(11):2171-2181.
4. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719-1724.
5. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
6. Riva S, Camerini AL, Allam A, Schulz PJ. Interactive sections of an Internet-based intervention increase empowerment of chronic back pain patients: randomized controlled trial. J Med Internet Res. 2014;16(8):e180.
7. Riva S, Schulz P, Staffoni L, Schoeb V. Patient participation in discharge planning decisions in the frame of primary nursing approach: a conversation analytic study. Stud Commun Sci. 2014; 14(1):61-67.
8. Schulz PJ, Hartung U, Riva S. Causes, coping, and culture: a comparative survey study on representation of back pain in three Swiss language regions. PLoS ONE. 2013;8(11):e78029.
9. Baldi PL, Iannello P, Riva S, Antonietti A. Cognitive reflection and socially biased decisions. Stud Psychol (Bratisl). 2013;5(4): 265-271.
10. Riva S, Monti M, Iannello P, Pravettoni G, Schulz PJ, Antonietti A. A preliminary mixed-method investigation of trust and hidden signals in medical consultations. PLoS ONE. 2014; 9(3):e90941.
11. Guastafierro S, Falcone U, Celentano M, Coppola M, Ferrara MG, Sica A. Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk Res. 2009;33(8):1079-1081.
12. Mahon FX, Fort MP, Etienne G, et al. Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation. Blood. 2010;116:2299 (abstract). ASH Annual Meeting Abstracts.
13. Mahon FX, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
14. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012;10(Suppl 3):S1-S13.
15. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10(1):14-24.
16. Sweet K, Oehler V. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider? Hematology (Am Soc Hematol Educ Program). 2013;2013(1):184-188.
17. Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica. 2014; 99(2):205-208.
18. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104(7):2204-2205.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349.
20. Gorini A, Mazzocco K, Gandini S, Munzone E, McVie G, Pravettoni G. Development and psychometric testing of a breast cancer patient-profiling questionnaire. Breast Cancer (Dove Med Press). 2015;7:133-146.
21. Zaleskiewicz T. Beyond risk seeking and risk aversion: personality and the dual nature of economic risk taking. Eur J Pers. 2001;15(S1):S105-S122.
22. Webster DM, Kruglanski AW. Individual differences in need for cognitive closure. J Pers Soc Psychol. 1994;67(6):1049-1062.
23. Keinan R, Bereby-Meyer Y. "Leaving it to chance"-Passive risk taking in everyday life. Judgment and Decision Making. 2012;7(6):705-715.
24. Oreg S. Resistance to change: developing an individual differences measure. J Appl Psychol. 2003;88(4):680-693.